Filing Flows › Neogenomics (NEO) › Commercial insurance revenue
Neogenomics (NEO) Commercial insurance revenue by quarter
Neogenomics' Commercial insurance revenue was $44.7M in Q3 2026 (third quarter 2026), +23% from Q2 2026. Over the last 7 quarters it ranged from $24.9M (Q1 2025) to $44.7M (Q3 2026).
| Quarter | Commercial insurance revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $44.7M | +23% | +38% |
| Q2 2026 | $36.3M | +17% | +26% |
| Q1 2026 | $30.9M | -2% | +24% |
| Q4 2025 | $31.4M | -3% | — |
| Q3 2025 | $32.5M | +13% | — |
| Q2 2025 | $28.8M | +16% | — |
| Q1 2025 | $24.9M | — | — |
Q3 2026 at a glance
Neogenomics, Q3 2026: revenue $209M (+11% year over year), operating margin -3.8%, net loss $7.5M, operating cash flow −$8.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is Neogenomics' Commercial insurance revenue?
Neogenomics' Commercial insurance revenue was $44.7M in Q3 2026 (third quarter 2026), +23% from Q2 2026.
How has Neogenomics' Commercial insurance revenue changed?
Over the last 7 quarters it ranged from $24.9M (Q1 2025) to $44.7M (Q3 2026).